FibroBiologics and Charles River link for chronic disease therapies manufacture

By Yahoo! Finance | Oct 21, 2024 at 07:49 AM EST

FibroBiologics partners with Charles River Laboratories to manufacture cell-based therapies for chronic diseases, including CYWC628 for diabetic foot ulcers. This collaboration aims to advance regenerative medicine and transform patient care through innovative therapies.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.